Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Abstract: The modulator compounds described herein modulate muscarinic receptors and are useful for treating muscarinic receptor mediated diseases.

Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Abstract: The subject invention provides new progestogen esters and uses thereof.

Abstract: Provided herein are novel heteroaromatic substituted cyclopropanes of the Formula (I): as well as compositions, including pharmaceutical compositions, containing the same, and the use thereof in the treatment of various neurological and psychological disorders, e.g., anxiety and depression, treatable by antagonizing CRF receptors.

Abstract: The subject invention provides a contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15.

Abstract: Provided herein are novel heteroaromatic substituted cyclopropanes of the Formula (I): 1

Abstract: The invention relates to non-slow-binding thrombin inhibitors of the formula: A—B—C-Lys-D— wherein A is H, 2-hydroxy-3-cyclohexyl-proprionyl-, R1, R1—O—CO—, R1—SO2—, —(CHR2)nCOOR3, or an N-protecting group, wherein R1 is selected from -(1-6C)alkylene-COOH, (1-12C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the aryl group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy, or halogen; R2 is H or has the same meaning as R1, R3 is selected from H, (1-12C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the aryl group of which may be substitute with (1-6C)alkyl, (2-12C)alkoxy, hydroxy or halogen; n is an integer of 1 to 3; B is a bond, L-asp or an ester derivative thereof, Leu, norLeu, —N(benzyl)-CH2—CO—, —N(2-indane)-CH2—CO—, D-1 Piq, D-3 Piq, D-Tiq, Atc or a D-amino acid having a hydrophobic aromatic side chain; C is Azt, Pro, Pec, norLeu(cyclo)Gly, an

Abstract: The invention relates to non-slow-binding thrombin inhibitors of the formula: A—B—C-Lys-D wherein A is H, 2-hydroxy-3-cyclohexylpropionyl-, R1, R1—O—CO—, R1—CO—, R1—SO2—, —(CHR2)nCOOR3, or an N-protecting group, wherein R1 is selected from —(1-6C)alkylene-COOH, (1-12C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl; and (8-16C)aralkenyl, the aryl group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy, or halogen; R2 is H or has the same meaning as R1, R3 is selected from H, (1-12C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the aryl group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy or halogen; n is an integer of 1 to 3; B is a bond, L-Asp or an ester derivative thereof, Leu, norLeu, —N(benzyl)-CH2—CO—, —N(2-indane)-CH2—CO—, D-1-Piq, D-3-Piq, D-Tiq, Atc or a D-amino acid having a hydrophobic aromatic side chain; C is Azt, Pro, Pec, no

Abstract: The invention relates to non-slow-binding thrombin inhibitors of the formula: A-B-C-Lys-D wherein A is H, 2-hydroxy-3-cyclohexyl-propionyl-, R1, R1—O—CO—, R1—SO2—, —(CHR2)nCOOR3, or an N-protecting group, wherein R1 is selected from -(1-6C)alkylene-COOH, (1-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy, or halogen; R2 is H or has the same meaning as R1, R3 is selected from H, (112C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the aryl group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy or halogen; n is an integer of 1 to 3; B is a bond, L-Asp or an derivative thereof, Leu,norLeu, -n(benzyl)—CH2—CO—, -N(2-indane)—CH2—CO—, D-1Piq, D-Tiq, Atc or a D-amino acid having a hydrophobic aromatic side chain; C is Azt, Pro, Pec, norLeu(cyclo)Gly, an amino acid of one of the formulae -N[(3-8C)cycloalk

Abstract: The invention relates to a tuneable bisconjugate comprising two saccharides and a spacer, each saccharide being the same or different and comprising two to six monosaccharide units, at least one unit being uronic acid, characterized in that at least one of the saccharides per se has anti-thrombotic activity, and that the spacer connects at least one saccharide to the other through its non-reducing end, the chain length of the spacer being 20-120 atoms.